221 related articles for article (PubMed ID: 9612680)
1. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
Wolff JM; Bares R; Jung PK; Buell U; Jakse G
Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
[TBL] [Abstract][Full Text] [Related]
3. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
4. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
5. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
[TBL] [Abstract][Full Text] [Related]
6. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
7. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
[TBL] [Abstract][Full Text] [Related]
8. Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer.
Singh OP; Yogi V; Redhu P; Ghori HU; Pareek A; Lal N
J Cancer Res Ther; 2019 Mar; 15(Supplement):S39-S41. PubMed ID: 30900618
[TBL] [Abstract][Full Text] [Related]
9. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ
BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
[TBL] [Abstract][Full Text] [Related]
10. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
[TBL] [Abstract][Full Text] [Related]
12. Bone scanning--who needs it among patients with newly diagnosed prostate cancer?
Hirobe M; Takahashi A; Hisasue S; Kitamura H; Kunishima Y; Masumori N; Iwasawa A; Fujimori K; Hasegawa T; Tsukamoto T
Jpn J Clin Oncol; 2007 Oct; 37(10):788-92. PubMed ID: 17911377
[TBL] [Abstract][Full Text] [Related]
13. Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer?
Perachino M; Di Ciolo L; Barbetti V; Puppo P
Eur Urol; 1996; 29(3):366-9. PubMed ID: 8740025
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen.
Kataoka A; Yuasa T; Kageyama S; Tsuchiya N; Habuchi T; Iwaki H; Narita M; Okada Y; Yoshiki T
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):480-4. PubMed ID: 16909972
[TBL] [Abstract][Full Text] [Related]
16. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
Wang ZL; Wang XF
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
[TBL] [Abstract][Full Text] [Related]
17. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Haukaas S; Roervik J; Halvorsen OJ; Foelling M
Br J Urol; 1997 May; 79(5):770-6. PubMed ID: 9158517
[TBL] [Abstract][Full Text] [Related]
18. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
[TBL] [Abstract][Full Text] [Related]
19. The value of a baseline bone scan in patients with newly diagnosed prostate cancer.
Lin K; Szabo Z; Chin BB; Civelek AC
Clin Nucl Med; 1999 Aug; 24(8):579-82. PubMed ID: 10439178
[TBL] [Abstract][Full Text] [Related]
20. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?
Vijayakumar V; Vijayakumar S; Quadri SF; Blend MJ
Am J Clin Oncol; 1994 Oct; 17(5):432-6. PubMed ID: 7522394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
